MDT Stock: +10% Revenue Growth but GLP-1 Still Haunts Diabetes Q2 FY2026

YEXT Stock: $140M Buyback + Guide Suspended Q1 FY2027

Yext Q1 FY2027 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, STRONG) - CURRENT @ $3.89 - HOLD - BUY below $3.31 with $2.72 stop - AVOID above $5.25 TRIGGER: Two consecutive quarters of positive total ARR growth with the under-$50K ACV cohort decline narrowing to single digits OR restoration of forward guidance WINDOW: Through Q3 FY2027 earnings (December 2026) TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 3 Buy / 5 Hold / 1 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $6.00 (range $4 - $8) - Charged Alpha vs consensus: IN LINE THESIS Yext is a deep-value mid-cap search-marketing SaaS name: 1.4x EV/Sales, 17.6% FCF yield, $440.8M of total ARR, and management has explicitly chosen capital return over reinvestment. The $140M tender retired 17% of the share count in a single move. But topline is flat, the small-customer book is in 19% YoY decline, and forward guidance is withdrawn. Bull lever: If total ARR stabilizes and EBITDA stays at 25% margin while the open-market $100M authorization keeps retiring shares, equity value compounds even on flat revenue - a re-rating from 1.4x to 2.0x EV/Sales is roughly a 45% equity move from $3.89 toward $5.65. Key risk: Total ARR turns negative as the under-$50K cohort decline accelerates, EBITDA margin compresses on AI infrastructure costs, and the suspended guidance hides the deterioration - the stock drifts toward the $3.265 52-week low. QUALITY CHECK - Management quality grade: B (CEO Michael Walrath has been clear and consistent about the pivot to capital return. The $140M tender is decisive, and the $100M open-market authorization on top is shareholder-friendly. But suspending forward guidance and quarterly earnings calls in the same quarter raises information-asymmetry concerns for public-equity investors. The execution-first posture is credible; the transparency reduction is the offset.) - Earnings quality grade: B (Cash conversion is excellent - Q1 FCF of $37M against $2.6M of GAAP net income reflects working-capital tailwinds and strong unit economics. SBC at 9.3% of revenue is at the SaaS peer median. The balance sheet is more leveraged after the tender: $91.9M cash against $224.7M total debt, a net debt position of approximately $133M.) CHAPTERS 0:00 Hook 0:15 S0b_Year 0:53 The Print 1:45 S1b_BeatDecomp 2:24 The Trend 3:06 The Segments 3:48 The FCF Bridge 4:46 S4b_MarginQual 5:38 Guidance & The Narrative Diff 7:00 S5b_Catalyst 7:44 Peer Dot-Plot 8:40 S6b_Valuation 9:33 Management & Earnings Quality 10:41 S8a_Call 11:30 S8b_Call KEY METRICS - Q1 FY2027 - Revenue: $0.11B (YoY -1.5%, beat est by -0.1%) - EPS: $0.15 (vs $0.13 est, beat +15.4%) - Operating margin: 5.2% - Free cash flow: $0.04B (34.3% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q4 FY26 call, CEO Michael Walrath said: We are pivoting Yext to a capital-return story. The platform throws off cash, and shareholders should benefit from that directly." - This call: "We completed a $140 million tender offer and retired 24.3 million shares. We are also discontinuing quarterly earnings calls and forward guidance so the team can focus entirely on execution and product." - Tone shift: Beat on Q1 EBITDA by roughly $5M and non-GAAP EPS by two cents. The hard number was the 25% adj EBITDA margin. The structural change was 24.3M shares retired in a single transaction - about 17% of the share count - and a $100M open-market authorization increase on top. The disappointment was the guidance pull and the call discontinuation, which the market reads as a transparency reset. DATA SOURCES - FMP (financialmodelingprep.com) - Yext Q1 FY2027 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in YEXT. Do your own research before any investment decision. #YEXT #Yext #earnings #investing #stocks #ChargedAlpha

NX Stock: EPS Beat +19% + Custom Solutions +6.6% Q2 FY2026

Quanex Building Products Q2 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $22.85 - HOLD - BUY below $20.00 with $17.00 stop - AVOID above $28.00 TRIGGER: Two consecutive quarters of revenue beat AND Custom Solutions segment growth above +5% OR Tyman synergy run-rate disclosed above $30M annualized WINDOW: Through Q4 FY2026 earnings (December 2026) TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 4 Buy / 3 Hold / 0 Sell / 0 Strong Sell - BUY - Median 12-month price target: $28.00 (range $24 - $32) - Charged Alpha vs consensus: MORE CAUTIOUS THESIS Quanex is a post-Tyman acquisition consolidation play in the building products space. Q2 FY2026 EPS beat by +19% on Custom Solutions strength, but revenue missed for the second straight quarter. Mid-East logistics + tariff headwinds are concrete near-term cost pressures. Bull lever: Custom Solutions segment +6.6% YoY (volume + pricing); non-GAAP EPS beat +19%; FY2026 guidance maintained; 8.5% FCF yield with forward PE of 11.6x; analyst PT of $28.50 implies 25% upside. Key risk: Mid-East war driving transportation + raw material costs; tariff exposure on imported aluminum/vinyl components; housing renovation cycle softening; $0.21 GAAP-to-non-GAAP gap reflects Tyman amortization that must wind down. QUALITY CHECK - Management quality grade: B (CEO George Wilson is leading the integration of the FY2025 Tyman PLC acquisition - a transformative deal that doubled Quanex's revenue base. Year two of integration shows Custom Solutions segment outperforming and synergy realization on track per management commentary. Maintained guidance despite revenue miss signals operational confidence. The test: delivering the FY26 EPS midpoint of $1.55 (+21% YoY) requires second-half housing season cooperation.) - Earnings quality grade: C (Non-GAAP EPS $0.25 vs GAAP $0.04 - the $0.21 per-share gap reflects heavy Tyman acquisition amortization, integration costs, and restructuring. The adjusted metric is the appropriate operating read but the gap warrants tracking through FY27 as amortization should taper. SBC at ~26% of FCF is elevated. Working capital headwind from inventory build for second-half season.) CHAPTERS 0:00 Hook 0:13 S0b_Year 0:59 The Print 1:43 S1b_BeatDecomp 2:26 The Trend 3:19 The Segments 3:59 The FCF Bridge 4:52 S4b_MarginQual 5:43 Guidance & The Narrative Diff 6:48 S5b_Catalyst 7:25 Peer Dot-Plot 8:19 S6b_Valuation 9:09 Management & Earnings Quality 9:57 S8a_Call 10:37 S8b_Call KEY METRICS - Q2 FY2026 - Revenue: $0.46B (YoY +2.0%, beat est by -2.3%) - EPS: $0.25 (vs $0.21 est, beat +19.0%) - Operating margin: 3.2% - Free cash flow: $0.02B (3.8% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q1 FY2026 call, CEO George Wilson said: We are delivering on Tyman synergy targets and positioning the portfolio for the second half housing season. Custom Solutions is showing strong momentum." - This call: "Custom Solutions delivered another strong quarter with sales up 6.6 percent on both volume and pricing improvement. We are managing through transportation and raw material cost pressures from the Mid-East conflict and remain confident in our full-year outlook." - Tone shift: Mixed: revenue light by $10.7M but EPS beat by $0.04 on Custom Solutions segment outperformance. GAAP EPS of $0.04 reflects Tyman acquisition amortization; non-GAAP $0.25 is the clean read. Mid-East war shipping disruption flagged as new cost pressure on top of existing tariff headwinds. Management maintained guidance - confidence signal but no upside raise. DATA SOURCES - FMP (financialmodelingprep.com) - Quanex Building Products Q2 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in NX. Do your own research before any investment decision. #NX #QuanexBuildingProducts #earnings #investing #stocks #ChargedAlpha

CURV Stock: Sales Beat Guide + EBITDA Hi-End Q1 FY2026

Torrid Q1 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $1.64 - HOLD - BUY below $1.25 with $0.95 stop - AVOID above $2.50 TRIGGER: Q2 FY2026 showing comp sales above -1.0% AND gross margin recovery to 36%+ - two confirmatory data points before adding WINDOW: Through Q3 FY2026 earnings (December 2026) - the footwear reset proof point TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 1 Buy / 5 Hold / 2 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $2.00 (range $1 - $4) - Charged Alpha vs consensus: IN LINE THESIS Torrid Holdings is a deep-value microcap turnaround. Q1 FY2026 print cleared a low bar with revenue above guide and FY26 EBITDA outlook above Street - driving an 18 percent relief rally. But the underlying revenue declined 7.6 percent YoY, comp sales fell 1.7 percent, and gross margin compressed 280 basis points. The setup is binary: footwear and tariff normalization in 2H deliver the bull case, or a stuck-in-decline year delivers another leg lower. Bull lever: FY26 Adj EBITDA guide of $70M midpoint above $69.4M Street; revenue beat the guidance bar; comp sales decelerating to -1.7% from -5.5% trough; 18% FCF yield on guide implementation; deep-value microcap with squeeze optionality below $2. Key risk: Six straight quarters of YoY revenue decline; gross margin compressed 280bps on tariffs and footwear clearance; competition from Old Navy, Target, Walmart plus-size lines is structural; comp sales negative in 7 of last 8 quarters; fleet shrunk from 624 to 463 stores in 4 years. QUALITY CHECK - Management quality grade: C+ (CEO Lisa Harper has executed the brand health and inventory discipline initiative without dramatic strategic pivot. The fleet rationalization is on track and FY26 EBITDA guide came in above Street. But six straight quarters of YoY revenue decline is on management's watch, and the footwear assortment miss is a merchandising error. Harper deserves credit for stabilizing margins from the Q4 FY2025 trough, not credit for a turnaround that has not yet inflected.) - Earnings quality grade: C+ (GAAP EPS rounded to $0.00 - actual $0.0042 - on $0.4M net income. There is no separately disclosed adjusted EPS metric; the cleaner read is Adj EBITDA of $17.6M, which hit the high end of guidance. Working capital build of $8M reflects inventory positioning for footwear reset. SBC at $2.5M is reasonable relative to the size of the company. The print does not contain meaningful one-time gains or charges that distort the operating picture.) CHAPTERS 0:00 Hook 0:13 S0b_Year 1:07 The Print 1:59 S1b_BeatDecomp 2:52 The Trend 3:52 The Segments 4:37 The FCF Bridge 5:33 S4b_MarginQual 6:35 Guidance & The Narrative Diff 7:48 S5b_Catalyst 8:30 Peer Dot-Plot 9:29 S6b_Valuation 10:19 Management & Earnings Quality 11:27 S8a_Call 12:14 S8b_Call KEY METRICS - Q1 FY2026 - Revenue: $0.25B (YoY -7.6%, beat est by +2.5%) - EPS: $0.00 (vs $-0.02 est, beat +100.0%) - Operating margin: 3.5% - Free cash flow: $0.00B (1.2% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q4 FY2025 call, CEO Lisa Harper said: We are executing on our brand health initiatives, prioritizing assortment quality and inventory discipline. We expect FY2026 to be a year of stabilization, with a return to growth as our footwear assortment refreshes through the back half." - This call: "Our first quarter results came in at the high end of our guidance ranges, and we are reaffirming our full-year outlook. We see continued normalization of footwear by the third quarter, and we are taking a disciplined approach to managing tariffs and promotions." - Tone shift: Beat revenue by $5.9M (2.5%) and broke even on EPS versus expected loss. Adj EBITDA hit the high end of the $14-17M guide range. The market reaction tells the story - at $1.39 entering the print and $1.64 exiting (+18%), the print cleared a very low bar. The FY26 EBITDA guide at $70M midpoint, just above the $69.4M Street figure, was the unlock. Comp sales -1.7% with a +1.2% ex-footwear bridge gave bulls a narrative. DATA SOURCES - FMP (financialmodelingprep.com) - Torrid Q1 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in CURV. Do your own research before any investment decision. #CURV #Torrid #earnings #investing #stocks #ChargedAlpha

CURV Stock: Sales Beat Guide + EBITDA Hi-End Q1 FY2026

Torrid Q1 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $1.64 - HOLD - BUY below $1.25 with $0.95 stop - AVOID above $2.50 TRIGGER: Q2 FY2026 showing comp sales above -1.0% AND gross margin recovery to 36%+ - two confirmatory data points before adding WINDOW: Through Q3 FY2026 earnings (December 2026) - the footwear reset proof point TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 1 Buy / 5 Hold / 2 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $2.00 (range $1 - $4) - Charged Alpha vs consensus: IN LINE THESIS Torrid Holdings is a deep-value microcap turnaround. Q1 FY2026 print cleared a low bar with revenue above guide and FY26 EBITDA outlook above Street - driving an 18 percent relief rally. But the underlying revenue declined 7.6 percent YoY, comp sales fell 1.7 percent, and gross margin compressed 280 basis points. The setup is binary: footwear and tariff normalization in 2H deliver the bull case, or a stuck-in-decline year delivers another leg lower. Bull lever: FY26 Adj EBITDA guide of $70M midpoint above $69.4M Street; revenue beat the guidance bar; comp sales decelerating to -1.7% from -5.5% trough; 18% FCF yield on guide implementation; deep-value microcap with squeeze optionality below $2. Key risk: Six straight quarters of YoY revenue decline; gross margin compressed 280bps on tariffs and footwear clearance; competition from Old Navy, Target, Walmart plus-size lines is structural; comp sales negative in 7 of last 8 quarters; fleet shrunk from 624 to 463 stores in 4 years. QUALITY CHECK - Management quality grade: C+ (CEO Lisa Harper has executed the brand health and inventory discipline initiative without dramatic strategic pivot. The fleet rationalization is on track and FY26 EBITDA guide came in above Street. But six straight quarters of YoY revenue decline is on management's watch, and the footwear assortment miss is a merchandising error. Harper deserves credit for stabilizing margins from the Q4 FY2025 trough, not credit for a turnaround that has not yet inflected.) - Earnings quality grade: C+ (GAAP EPS rounded to $0.00 - actual $0.0042 - on $0.4M net income. There is no separately disclosed adjusted EPS metric; the cleaner read is Adj EBITDA of $17.6M, which hit the high end of guidance. Working capital build of $8M reflects inventory positioning for footwear reset. SBC at $2.5M is reasonable relative to the size of the company. The print does not contain meaningful one-time gains or charges that distort the operating picture.) CHAPTERS 0:00 Hook 0:13 S0b_Year 1:07 The Print 1:59 S1b_BeatDecomp 2:52 The Trend 3:52 The Segments 4:37 The FCF Bridge 5:33 S4b_MarginQual 6:35 Guidance & The Narrative Diff 7:48 S5b_Catalyst 8:30 Peer Dot-Plot 9:29 S6b_Valuation 10:19 Management & Earnings Quality 11:27 S8a_Call 12:14 S8b_Call KEY METRICS - Q1 FY2026 - Revenue: $0.25B (YoY -7.6%, beat est by +2.5%) - EPS: $0.00 (vs $-0.02 est, beat +100.0%) - Operating margin: 3.5% - Free cash flow: $0.00B (1.2% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q4 FY2025 call, CEO Lisa Harper said: We are executing on our brand health initiatives, prioritizing assortment quality and inventory discipline. We expect FY2026 to be a year of stabilization, with a return to growth as our footwear assortment refreshes through the back half." - This call: "Our first quarter results came in at the high end of our guidance ranges, and we are reaffirming our full-year outlook. We see continued normalization of footwear by the third quarter, and we are taking a disciplined approach to managing tariffs and promotions." - Tone shift: Beat revenue by $5.9M (2.5%) and broke even on EPS versus expected loss. Adj EBITDA hit the high end of the $14-17M guide range. The market reaction tells the story - at $1.39 entering the print and $1.64 exiting (+18%), the print cleared a very low bar. The FY26 EBITDA guide at $70M midpoint, just above the $69.4M Street figure, was the unlock. Comp sales -1.7% with a +1.2% ex-footwear bridge gave bulls a narrative. DATA SOURCES - FMP (financialmodelingprep.com) - Torrid Q1 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in CURV. Do your own research before any investment decision. #CURV #Torrid #earnings #investing #stocks #ChargedAlpha

HCM Stock: FRUZAQLA +26% + SAFFRON Readout Q1 2026

HUTCHMED H1 2026 Preview earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $10.87 - HOLD - BUY below $9.50 with $8.00 stop - AVOID above $18.00 TRIGGER: SAFFRON Phase III topline readout (window late Q3 2026) WINDOW: Through SAFFRON readout (~3-4 months) TRACKER: chargedalpha.com/track/HCM WALL STREET CONSENSUS - Ratings: 2 Strong Buy / 3 Buy / 6 Hold / 1 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $18.50 (range $12 - $28) - Charged Alpha vs consensus: ALIGNED THESIS FRUZAQLA royalty stream + $1.4B cash floor + binary SAFFRON optionality Bull lever: SAFFRON Phase III hits - savolitinib global label, $200M+ in royalties Key risk: SAFFRON Phase III misses - savolitinib thesis impairment, $200M+ R&D writedown QUALITY CHECK - Management quality grade: B+ (CEO Weiguo Su has led HUTCHMED through the FRUZAQLA US/EU launch and the Takeda global partnership - both validate HUTCHMED's drug-development engine. The Hutchison Sinopharm divestiture cleaned up the cap table and added $415.8M in cash. SAFFRON Phase III outcome is the next test of scientific judgement; the company has been disciplined on R&D allocation.) - Earnings quality grade: C+ (FY2025 GAAP EPS of $2.66 was overwhelmingly driven by a $415.8M one-time Sinopharm divestiture gain. The underlying operating result was a $7M loss with negative op margin. Adjusted EPS of $0.22 missed by a small amount. Investors should treat GAAP as non-recurring; the $0.22 adj is the clean operating read.) CHAPTERS 0:00 Hook 0:10 S0b_Year 0:38 The Print 1:12 S1b_BeatDecomp 1:41 The Trend 2:38 The Segments 3:08 The FCF Bridge 4:02 S4b_MarginQual 4:33 Guidance & The Narrative Diff 5:32 S5b_Catalyst 8:16 Peer Dot-Plot 8:44 S6b_Valuation 9:13 Management & Earnings Quality 10:52 S8a_Call 11:20 S8b_Call KEY METRICS - H1 2026 Preview - Revenue: $n/aB (YoY -15.0%, beat est by +2.5%) - EPS: $2.66 (vs $0.22 est, beat +1109.0%) - Operating margin: n/a% - Free cash flow: $0.09B (15.5% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "FRUZAQLA US launch ramp is the near-term value driver; SAFFRON readout 2026." - This call: "FRUZAQLA +26% in-market YoY; Sinopharm sold; SAFFRON readout this summer." - Tone shift: Revenue +2.5% vs estimate; FRUZAQLA royalties accelerating; SAFFRON timing tightened. DATA SOURCES - FMP (financialmodelingprep.com) - HUTCHMED H1 2026 Preview press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in HCM. Do your own research before any investment decision. #HCM #HUTCHMED #earnings #investing #stocks #ChargedAlpha